Treatment and Monitoring

Size: px
Start display at page:

Download "Treatment and Monitoring"

Transcription

1 Treatment and Monitoring

2 Disclosures We have no actual or potential conflicts of interest in relation to this presentations. We have no financial relationships to disclose.

3 Learning Objectives After this session, participants will be able to: Discuss the team members involved in managing care Describe the TB treatment regimens

4 Case Management Process Interview Phase Case Interview Assessment Address Barriers to Adherence Contact Investigation Plan Treatment and Monitoring Completion of Treatment

5 Managing TB care Collaboration with the private provider, if there is one, is critical If a private provider is involved negotiate Monthly assessments Sputum collection Radiography Vision and auditory exams laboratory monitoring Other assessments needed DOT will most often be done by the Health Department A contact investigation is the responsibility of the health department. This is Pure public health

6 Amelia Her story continues She lives with her boyfriend and her 3 children ages 2, 6 and 7. Her sister, brother-in-law and their 2 young children also live in the home. She works at night and her boyfriend works during the day. She has not been at work for over over one month and her boyfriend has stayed home to watch the children. She was told she had diabetes 3 years ago. Amelia has no insurance. The hospitalist explained that upon discharge the health department needs to monitor from then on.

7 Team Members Who is involved in every TB case in your area? Who would be part of the team caring for Amelia day to day? Do roles overlap?

8 Treatment of Drug Susceptible TB Guidelines 2016 Utilize case management interventions during treatment of cases with tuberculosis

9 Key Treatment Regimen Highlights DOT is the standard of care. Daily (5 or 7) rather than intermittent dosing during the initial (intensive) phase is recommended. Daily or three times weekly (TIW) dosing in the continuation phase is recommended. Alternative regimens that are variations of the preferred regimen may be acceptable in certain clinical and public health siturations. Once weekly regimens(inh/rpt) in the continuation phase should not be used. 4 month regimens are adequate for HIV (-), culture (-) adults.

10 Key Treatment Highlights - HIV Positive TB Cases Preference is to not use an intermittent regimen. 6 months of daily treatment can be used if the case is taking Antiretroviral s (ARV) during TB therapy. Those who are not on ARV should receive no less than 9 months of TB therapy. For those who are not on ARV s when diagnosed with TB ARV therapy should be initiated within the first two weeks in those with CD4 counts less than 50/mm and within 8-12 weeks in those with CD4 counts greater than 50/mm Those who are diagnosed with TB Meningitis SHOULD NOT start ARV prior to completing 8-10 weeks of TB therapy regardless of their CD4 count.

11 TB Drugs Rifampin Isoniazid Pyrazinamide Ethambutol RIPE Essential for short-course TB regimens Turns body fluids orange Flu like symptoms Cousin to rifabutin, & rifapentine Used only for TB Headache, nausea, fatigue neuropathy Tyramine food reaction Bactericidal Used only for TB Works best early in treatment Achy joints (arthralgia) Bactericidal & Bacteriostatic Safety net drug Color vision Vision acuity Stomach issues Bacteriostatic Bactericidal ALL: rash, nausea, fatigue, abdominal pain, drug fever

12 TB Treatment Regimens Insert graphic of new chart Page 4

13 The Two Phases of a Standard TB Treatment Regimen No longer recommended Time in months Initial Phase Continuation Phase

14 4 drugs Initial Phase Exceptions - pregnancy/ no PZA Exceptions - young children / some may exclude EMB 2 regimens, 1 & 2 are daily dosing Regimen 3 is TIW for 24 doses Regimen 4 begins with daily, ends with BIW

15 Time for math!

16 Calculating Dosages All medication dosages are calculated based on milligram/kilogram. Therefore to determine if RIPE dosing is correct you must convert pounds (lbs.) to kilograms (kg.) 160 lbs. 2.2 = 72.7 kg.

17 Treatment Quirks Daily does not simply mean 7 days/week. It means 5 days/week most of the time. Treatment weeks calendar weeks. Calculate treatment weeks Total doses taken Frequency of administration = Total treatment weeks.to determine if treatment is complete.

18 More Treatment Quirks 6 months of treatment 24 weeks, it equals 26 weeks because 52/2=26 Months Weeks Initial phase Continuation phase 6 = = = = 52 No true initial phase/ continuation phase Surprise! Surprise! Many patients do not complete treatment exactly by the book.

19 PZA and EMB - Whole Tablet Dosing Page 26

20 PZA and EMB - Whole Tablet Dosing wgt. 150# (68.2kg) = PZA 3, EMB 3 Page 26

21 PZA and EMB - Whole Tablet Dosing There will likely be the same # of tablets for both wgt. 150# (68.2kg) = PZA 3, EMB 3 Page 26

22 Treating Amelia What s emphasized

23 Amelia weighs 126 lbs Calculate her weight in kilograms Adult dosing Rifampin 10mg/kg Isoniazid 5mg/kg Pyrazinamide chart page 26 Ethambutol chart pg 26

24 Reactions requiring immediate report Hold medication Jaundice Dark urine Vomiting Abdominal pain Fever Visual changes Marked rash

25 Reactions requiring a report in 24 hrs Do not hold without an order Anorexia Nausea Malaise Peripheral neuropathy Rashes

26 Addressing Treatment Complaints Common, manageable side effects Fatigue Nausea Rash without hives Headache Tyramine reaction Peripheral neuritis Arthralgias Sunburn

27 Common Problems/Simple Solutions (1) Fatigue take meds at the end of the day Reassure should improve with time GI symptoms/dyspepsia Light meal Stomach acid reducers

28 Common Problems/Simple Solutions (2) Rash Questions to Ask Has this happened in the past? When does it happen? Localized or generalized? Itchy? Painful? Hot? Dry? Do not presume it is an allergic reaction Topical treatment: corticosteroids, topical anesthetics or antihistamines Oral antihistamines Moisturizing may help

29 Common Problems/Simple Solutions (3) Headache Take medication later in the day Improve nutritional intake Tyramine reaction Self limiting: headache, palpitations, upper body flushing and itching, Consider food preferences Not an allergic reaction but consider antihistamines

30 Common Problems/Simple Solutions (4) Peripheral Neuritis Diabetic? Vitamin B6/pyridoxine: 25, 50, 75, 100 and beyond Arthralgias Other co-morbidity Likely Rifamycin? (generalized) Likely PZA? (joints) Menopause? Mild analgesic

31 Common Problems/Simple Solutions (5) Sunburn Stay out of sun, HOWEVER, may not be as easy Wear protective cotton clothing Use sun block!

32 Amelia s Story She lives with her boyfriend and her 3 children ages 2, 6 and 7. Her sister, brother-in-law and their 2 young children also live in the home She works at night and her boyfriend works during the day. She has not been at work for over over one month and her boyfriend has stayed home to watch the children. She was told she had diabetes 3 years ago. Amelia has no insurance. The hospitalist explained that upon discharge the health department needs to monitor from then on.

33 Factors that could Impact Treatment Obvious Currently unemployed Infectious young children in home Diabetic access to care? Uninsured comorbidity management? Evaluation of young children Potential Fear/isolation/guilt Treatment may be effected by diabetes

34 Going back to work Life happens! DOT Flexibility Location, Time, Frequency Moving Working with other jurisdictions Reporting district maintains case management responsibility Working district communicates status Provide labs, DOT records Family/Friend difficulty Living arrangements Broken relationships

35

36

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Initiation Phase Part 1 Ginny Dowell, RN, BSN February 4, 2015 Ginny Dowell RN, BSN has the following disclosures to make:

More information

LTBI Videos-Treatment

LTBI Videos-Treatment LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of

More information

Drug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment

Drug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment Drug Resistant Tuberculosis Self-reporting of Drugrelated Adverse Events During Treatment Introduction This information has been prepared for people with tuberculosis (TB) that is resistant to the commonly

More information

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict

More information

Treatment of Active Tuberculosis

Treatment of Active Tuberculosis Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest

More information

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

Treatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27

Treatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27 TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS Treatment: First Line Drugs 1. ISONIAZID = INH Bacteriocidal against dividing organisms Dose = 300mg = one pill = well absorbed Good CNS penetration Can be

More information

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant

More information

Managing the Patients Response to TB Treatment

Managing the Patients Response to TB Treatment Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

TB Nurse Assessment. Ginny Dowell, RN, BSN October 21, 2015

TB Nurse Assessment. Ginny Dowell, RN, BSN October 21, 2015 TB Nurse Assessment Ginny Dowell, RN, BSN October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19-22, 2015 Wichita, KS EXCELLENCE EXPERTISE INNOVATION Ginny Dowell,

More information

Treatment of Latent TB Infection (LTBI)

Treatment of Latent TB Infection (LTBI) Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious

More information

Disclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t

Disclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t Selected Topics in LTBI June 2, 2015 Bijan Ghassemieh, MD Senior Fellow UW Division of Pulmonary/Critical Care Disclosures No disclosures or conflicts of interest to report Outline Special LTBI situations

More information

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either

More information

Anti Tuberculosis Medications: Side Effects & adverse Events

Anti Tuberculosis Medications: Side Effects & adverse Events Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,

More information

Standard TB Treatment

Standard TB Treatment Standard TB Treatment Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University

More information

Pediatric TB Intensive San Antonio, Texas October 14, 2013

Pediatric TB Intensive San Antonio, Texas October 14, 2013 Pediatric TB Intensive San Antonio, Texas October 14, 2013 Treatment of Tuberculosis in Children Jeffrey R. Starke, M.D. Professor of Pediatrics October 14, 2013 Jeffrey R. Starke, M.D. has the following

More information

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures

More information

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017 Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats Tuberculosis Facts Below are frequently asked questions about TB, and their answers. If you have additional questions you may contact the City of Ennis Department of Health Services at 972-875-1234 or

More information

Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Iris Barrera, RN April 11, 2018

Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Iris Barrera, RN April 11, 2018 Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Iris Barrera, RN April 11, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Iris Barrera,

More information

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

Dosage and Administration

Dosage and Administration SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,

More information

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Debbie Onofre, RN, BSN March 18, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict

More information

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard

More information

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018 Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million

More information

Latent tuberculosis infection

Latent tuberculosis infection EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent

More information

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 TB Nurse Case Management September 7-9, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Jessica Quintero, M.Ed., has the following disclosures

More information

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

TUBERCULOSIS. Presented By: Public Health Madison & Dane County TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any

More information

Northwestern Polytechnic University

Northwestern Polytechnic University Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions

More information

Tuberculosis: A Provider s Guide to

Tuberculosis: A Provider s Guide to Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency

More information

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures

More information

Pediatric Tuberculosis: The Essentials October 8, 2014

Pediatric Tuberculosis: The Essentials October 8, 2014 Pediatric Tuberculosis: The Essentials Ann M Loeffler, MD Randall Children s Hospital at Legacy Emanuel Portland, Oregon Curry International TB Center Disclosures Nothing to disclose Learning Objectives

More information

Contact Investigation and Prevention in the USA

Contact Investigation and Prevention in the USA Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis

More information

TB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects

TB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects TB Nurse Case Management San Antonio, TX April 1 3, 2014 TB Medications and Adverse Effects Debbie Onofre RN, BSN Nurse Consultant/ Nurse Educator Heartland National TB Center April 1, 2014 Debbie Onofre,

More information

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Managing Anti-TB Therapy Side Effects and Complications Lisa Armitige, MD, PhD May 9, 2012 Lisa Armitige, MD, PhD has the following

More information

INITIATING ART IN CHILDREN: Follow the six steps

INITIATING ART IN CHILDREN: Follow the six steps INITIATING ART IN CHILDREN: Follow the six steps STEP 1: DECIDE IF THE CHILD HAS CONFIRMED HIV INFECTION Child < 18 months: HIV infection is confirmed if the PCR is positive and the VL is more than 10,000

More information

At the end of this session, participants will be able to:

At the end of this session, participants will be able to: Advanced Concepts in Pediatric TB: Treatment of Tuberculosis Disease Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [with help from Andrea Cruz, M.D.] Objectives At the end

More information

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis? Tuberculosis Understanding, Investigating, Eliminating Jeff Maupin, RN Tuberculosis Control Nurse Sedgwick County Division of Health Objectives At the conclusion of this presentation, you will be able

More information

Official ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016)

Official ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016) Official ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016) APPENDIX C: DRUGS IN CURRENT USE The U.S. Food and Drug Administration (FDA) has approved

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI: Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global

More information

TREATMENT OF LATENT TB INFECTION (LTBI)...

TREATMENT OF LATENT TB INFECTION (LTBI)... July, 2018 Page 1 TABLE OF CONTENTS 6.0 TREATMENT OF LATENT TB INFECTION (LTBI)... 2 6.1 Overview... 2 6.2 Procedure for Initiation of LTBI Treatment... 4 6.3 Recommended LTBI Treatment Regimens... 5 6.4

More information

Latent TB Infection Treatment

Latent TB Infection Treatment Latent TB Infection Treatment Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulmonary/Critical Care/Occ Med UI Carver College of Medicine 2014 MFMER slide-1 Disclosures: None

More information

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Monitoring Patients for TB Adverse Reactions and Managing Side Effects Catalina Navarro, RN, BSN April 11, 2014 Catalina Navarro, RN,

More information

Tuberculosis medications: adverse drug reactions

Tuberculosis medications: adverse drug reactions Tuberculosis medications: adverse drug reactions Rajesh M. Prabhu, M.D. Infectious Diseases Essentia Health, Duluth, MN July 25, 2017 2014 MFMER slide-1 No Finanial Disclosures Learning Objectives 1. Describe

More information

Tuberculosis Tools: A Clinical Update

Tuberculosis Tools: A Clinical Update Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features

More information

LTBI in Special Populations John Nava, MD October 5, 2010

LTBI in Special Populations John Nava, MD October 5, 2010 Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 LTBI in Special Populations John Nava, MD October 5, 2010 2 Treatment of Latent TB Infection in Special Populations John

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society

More information

Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with

More information

Clinical Case Scenario. HIVeEducation Workshop, Sint Maarten 2009

Clinical Case Scenario. HIVeEducation Workshop, Sint Maarten 2009 Clinical Case Scenario HIVeEducation Workshop, Sint Maarten 2009 Background Mrs. S is a 34 year-old woman who was referred from the VCT center after testing HIV positive three weeks ago. Her husband recently

More information

Case Management of the TB/HIV Infected Patient

Case Management of the TB/HIV Infected Patient TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected

More information

TB in the Patient with HIV

TB in the Patient with HIV TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to

More information

TB Nurse Case Management San Antonio, Texas April 9-11, 2013

TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,

More information

TB Case Management Hepatitis

TB Case Management Hepatitis TB Case Management Hepatitis Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University

More information

TB Nurse Case Management

TB Nurse Case Management TB Nurse Case Management San Antonio, Texas March 2-4, 2011 TB Medications and Adverse Effects Debbie Onofre, RN, BSN March 3, 2011 Debbie Onofre, RN, BSN has the following disclosures to make: No conflict

More information

Chapter 5 Treatment for Latent Tuberculosis Infection

Chapter 5 Treatment for Latent Tuberculosis Infection Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI

More information

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014 What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks

More information

Monica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale

Monica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale Randomized Trial of lsoniazid as Secondary Prophylaxis for Prevention of Recurrent Pulmonary Tuberculosis in HIV-positive Patients After One Episode of Tuberculosis Monica Manandhar A. Study Purpose and

More information

Broward Oncology Associates, P.A. PATIENT INFORMATION

Broward Oncology Associates, P.A. PATIENT INFORMATION NAME: BIRTHDATE: AGE: LOCAL ADDRESS (Street city state zip): HOME TELEPHONE# CELL # SOCIAL SECURITY #: - - SEX MARITAL STATUS WHAT IS YOUR HT? WHAT IS YOUR WT? EMPLOYER WORK# SPOUSE'S NAME SPOUSE'S EMPLOYER

More information

Sharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center

Sharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International

More information

New Patient Intake Form

New Patient Intake Form 501 Islington Street, Suite 2B Portsmouth, NH 03801 P: 603-610-8882 F: 603-463-0943 New Patient Intake Form Personal Information Today s Date Name Age DOB: Phone: H ( ) W ( ) Cell ( ) Preferred Home Work

More information

Pediatric TB Intensive Houston, Texas

Pediatric TB Intensive Houston, Texas Pediatric TB Intensive Houston, Texas November 13, 2009 Treatment of Pediatric TB Jeffrey R. Starke, M.D. November 13, 2009 MANAGEMENT OF CHILDHOOD TUBERCULOSIS Jeffrey R. Starke, M.D. Professor of Pediatrics

More information

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased

More information

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis

More information

Objectives. 3HP and Flu Syndrome What is the Underlying Mechanism? Case #1 3/23/2016. Christina T. Fiske, MD MPH March 30, 2016

Objectives. 3HP and Flu Syndrome What is the Underlying Mechanism? Case #1 3/23/2016. Christina T. Fiske, MD MPH March 30, 2016 Objectives 3HP and Flu Syndrome What is the Underlying Mechanism? Christina T. Fiske, MD MPH March 30, 2016 Illustrate the side effect of 3HP flu like syndrome after its initiation to raise awareness in

More information

Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015

Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015 Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Catalina Navarro,

More information

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1 Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma

More information

Marcos Burgos, MD has the following disclosures to make:

Marcos Burgos, MD has the following disclosures to make: Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures

More information

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES

More information

Patient History Form

Patient History Form Patient History Form Advanced Directive Care Plan? Yes No Name: Birth date: / / Address: Age: Sex: F M STREET DAY YEAR Telephone: Home ( ) CITY STATE DAY YEAR MARITAL STATUS: Divorced Separated Alive/Age

More information

TB and Comorbidities Adriana Vasquez, MD April 12, 2018

TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:

More information

Trastuzumab and Lapatinib

Trastuzumab and Lapatinib PATIENT EDUCATION patienteducation.osumc.edu What is Trastuzumab (tras-too-zoo-mab) and how does it work? Trastuzumab is a type of targeted cancer therapy called a monoclonal antibody. Another name for

More information

Patient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD

Patient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD Patient History 1 The Role of Surgery in the Management of TB Reynard McDonald, MD & Paul Bolanowski, MD September 16, 2010 42 y/o AA male was initially diagnosed with pansensitive pulmonary TB in 1986

More information

Blood Borne Pathogens. November 2010

Blood Borne Pathogens. November 2010 Blood Borne Pathogens November 2010 Objectives Meet requirements of OSHA Standard 29 CFR 1910.1030 OSHA Blood Borne Pathogens Post Test Routes of Transmission Types of Pathogens BSI / PPE Common Diseases

More information

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case

More information

PRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic

PRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic 0 PRODUCT MONOGRAPH FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION Anti-inflammatory, Analgesic INFORMATION FOR THE PATIENT FLOCTAFENINE, which has been prescribed to you

More information

Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation

Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation Randall Reves, MD, MSc TB Consultant Professor of Medicine and

More information

Augmentation Therapy. The Specific Therapy for Alpha-1 Lung Disease. Skinny Little Reference Guide

Augmentation Therapy. The Specific Therapy for Alpha-1 Lung Disease. Skinny Little Reference Guide Augmentation Therapy The Specific Therapy for Alpha-1 Lung Disease Skinny Little Reference Guide INTRODUCTION The FDA-approved therapy for the treatment of Alpha-1-related lung disease, specifically emphysema,

More information

Drug Side Effects and Toxicity

Drug Side Effects and Toxicity Drug Side Effects and Toxicity Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Toxicity Nausea and vomiting Any Drug Can Cause

More information

Diagnosis and Medical Management of Latent TB Infection

Diagnosis and Medical Management of Latent TB Infection Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,

More information

DRUG SIDE EFFECTS AND TOXICITY

DRUG SIDE EFFECTS AND TOXICITY DRUG SIDE EFFECTS AND TOXICITY Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Objectives After participating in this lecture,

More information

MEDICAL ASSESSMENT PART 1 - SOCIAL HISTORY

MEDICAL ASSESSMENT PART 1 - SOCIAL HISTORY Smoking history Alcohol history Never Quit Never Quit PART 2 - MEDICAL HISTORY Date of last colonoscopy? Date of last mammogram? Date of last pap smear? Date of last flu vaccine? Date of last pneumonia

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Priftin) Reference Number: CP.PMN.05 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Helath Plan Revision Log See Important Reminder at the end of this policy

More information

TB Intensive San Antonio, Texas May 7-10, 2013

TB Intensive San Antonio, Texas May 7-10, 2013 TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant

More information

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Managing Complex TB Cases Diana M. Nilsen, MD, RN Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private

More information

PEOPLE ARE TAKING WORKS FOR THEM. Ask your healthcare provider if it could work for you, too. a medication that

PEOPLE ARE TAKING WORKS FOR THEM. Ask your healthcare provider if it could work for you, too. a medication that 5 PEOPLE ARE TAKING a medication that WORKS FOR THEM. Ask your healthcare provider if it could work for you, too. Could TRIUMEQ be an HIV-1 treatment for you to move forward with? Whether you re considering

More information

Personal Health Risk Appraisal

Personal Health Risk Appraisal Today s Date: Premier Arthritis and Osteoporosis Center 722 North Fairfield Road Beavercreek, OH 45434 Phone (937) 208-7000 Fax (937) 208-7010 Personal Health Risk Appraisal Last Name: First Name: MI:

More information

Information. Leprosy can be easily cured. for the Patient

Information. Leprosy can be easily cured. for the Patient Information for the Patient About leprosy They will be cured of leprosy if they take the drugs in the blister packs as advised. They must complete a full course of treatment: 6 blisters for PB patients

More information

TB in the Correctional Setting Florence, Arizona October 7, 2014

TB in the Correctional Setting Florence, Arizona October 7, 2014 TB in the Correctional Setting Florence, Arizona October 7, 2014 Diagnosis and Treatment of TB Disease Renuka Khurana, MBBS, MPH October 7, 2014 Renuka Khurana, MSSB, MPH has the following disclosures

More information

Medication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011

Medication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Medication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011 Alisha Blair, LVN, has the following disclosures to make:

More information

MEDICATION GUIDE Abacavir, Lamivudine and Zidovudine Tablets (a-bak-a-vir, la-miv-ue-deen, zye-doe-vue-deen)

MEDICATION GUIDE Abacavir, Lamivudine and Zidovudine Tablets (a-bak-a-vir, la-miv-ue-deen, zye-doe-vue-deen) MEDICATION GUIDE Abacavir, Lamivudine and Zidovudine Tablets (a-bak-a-vir, la-miv-ue-deen, zye-doe-vue-deen) What is the most important information I should know about abacavir, lamivudine and zidovudine

More information

REDROCK MEDICAL GROUP INITIAL HISTORY AND PHYSICAL

REDROCK MEDICAL GROUP INITIAL HISTORY AND PHYSICAL REDROCK MEDICAL GROUP INITIAL HISTORY AND PHYSICAL NAME: BIRTH DATE: AGE: SEX: M F OCCUPATION: RACE: WHO REFERRED YOU TO OUR OFFICE? _ WHAT IS YOUR MAIN COMPLAINT? HOW LONG HAS THIS BEEN A PROBLEM? IS

More information

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 TB Case Presentation Andrea Cruz, MD, MPH August 14, 2014 Andrea Cruz, MD, MPH has the following disclosures to

More information

nevirapine, stavudine and lamivudine

nevirapine, stavudine and lamivudine nevirapine, stavudine and lamivudine Information on starting treatment with: nevirapine (NVP) + stavudine (d4t) + lamivudine (3TC) Nevirapine, stavudine and lamivudine (non-fixed dose) 2 Lead in dosing

More information

Efavirenz, stavudine and lamivudine

Efavirenz, stavudine and lamivudine efavirenz, stavudine, lamivudine: 1 efavirenz, stavudine and lamivudine First line ART treatment for HIV infection Efavirenz, stavudine and lamivudine efavirenz, stavudine, lamivudine: 2 Slide 1 Information

More information

TB in Corrections Phoenix, Arizona

TB in Corrections Phoenix, Arizona TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests

More information